Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Inhibrx
company
About
Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates.
- 51 - 100
Highlights
Details
- Last Funding Type
- Convertable Note
- Last Funding Money Raised
- $40M
- Industries
- Biotechnology,Therapeutics
- Founded date
- Jan 1, 2010
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology, orphan diseases and infectious diseases. Inhibrx has collaborations with Celgene and bluebird bio and has received awards from several granting agencies, including NIH, NIAID and CARB-X.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$40M
Inhibrx has raised a total of
$40M
in funding over 2 rounds. Their latest funding was raised on
May 21, 2019 from a Convertable Note round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 21, 2019 | Convertable Note | $40M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Inhibrx is funded by 1 investors.
Lilly Asia Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Lilly Asia Ventures
|
— | Convertable Note |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
